Table 1.
Clinical trials that evaluate L19 bound to different imaging agents.
| Name | Brand name | Phase | Total patients (age range) | Description | Cancer type and stage | Organization drug + (expected) publication | Study identifier |
|---|---|---|---|---|---|---|---|
| 123I‐L19 | NG | NG | 20 (34–79 years) | 123I‐labelled dimeric scFv(L19) antibody fragment | Brain (n = 2), lung (n = 16) or colorectal (n = 2) cancer | Amersham Pharmacia/Santimaria et al. (2003) | 800/II/I.27.15/1172 |
| 131I‐L19 | Radretumab | NG | 3 (27–73 years) | 131I‐labelled SIP composed of L19 | Lymphoma (n = 3) | Philogen S.p.A., GE Healthcare/Sauer et al. (2009) | Unknown |
| 131I‐L19 | Radretumab | I | 3 (NG) | 131I‐labelled SIP composed of L19 | Non‐small‐cell lung cancer (n = 3) | Philogen S.p.A., GE Healthcare/Erba et al. (2012) | NCT01124812 |
|
124I‐L19 131I‐L19 |
Radretumab | II | 6 (NG) | 124I‐labelled (PET) vs 131I‐labelled (SPECT) SIP composed of L19 | Non‐small‐cell lung cancer (n = 3), breast cancer (n = 3) | Philogen S.p.A., Advanced Center Oncology Macerata, GE Healthcare/Poli et al. (2013) | NCT01125085 |